Insulin aspart: A new rapid-acting insulin analog

Annals of Pharmacotherapy

Volumn 34, Issue 12, 2000, Pages 1423-1431

  Setter, Stephen M ^a   Corbett, Cynthia F ^b   Campbell, R Keith ^c   White, John R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Insulin analog; Insulin aspart

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE;

DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHELF LIFE;

AMINO ACID SEQUENCE; DATABASES, FACTUAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR SEQUENCE DATA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0033637840     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19414     Document Type: Review

References (38)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. From insulin to insulin analogs: Progress in the treatment of type 1 diabetes
4. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures
5. Decreased rate of hypoglycemia in association with improved metabolic control with insulin lispro
6. Less nocturnal hypoglycemia with insulin lispro in comparison to human regular
7. Insulin lispro improves postprandial blood glucose control in type 1 and type 2 diabetes without increasing the frequency of hypoglycemia
8. Improved glycemic control with insulin aspart; a multicenter randomized double-blind crossover trial in type 1 diabetic patients
9. Insulin aspart (IAsp) improves glycaemic control compared to human insulin (HI) for patients with type 1 diabetes
10. Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart
11. Improved long-term blood glucose control with insulin aspart versus human insulin in people with type 1 diabetes
12. Effects of the rapid-acting insulin analog insulin aspart on postprandial glycaemic excursions compared to human soluble insulin Actrapid given immediately or 30 minutes before a meal in insulin treated type 2 diabetes patients
13. Human insulin analog (insulin aspart, IAsp) is comparable to human insulin (HI) in type 2 diabetes
14. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study
15. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association of properties of B28 Pro →Asp insulin analogues
16. Insulin analogs with improved pharmacokinetic profiles
17. A study on self-mixing insulin aspart with NPH insulin in the syringe before injection
18. Fast acting human insulin analogs: A promising innovation in diabetes care
19. Insulin lispro: Its role in the treatment of diabetes mellitus
20. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (Asp(B9)Glu(B27), Asp(B10), Asp(B28)) in healthy subjects
21. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake
22. In vitro and in vivo potency of insulin analogues designed for clinical use
23. Monomeric insulins and their experimental and clinical implications
24. Comparison of subcutaneous soluble human insulin and insulin analogues (Asp(B9), Glu(B27); Asp(B10); Asp(B28)) on meal-related plasma glucose excursions in type I diabetic subjects
25. Monomeric insulins obtained by protein engineering and their medical implications
26. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers
27. Insulin secretion in the normal and diabetic human
28. Insulin therapy
29. Action profile of the rapid acting insulin analogue: Human insulin B28Asp
30. Insulin aspart (B28-asp-insulin): A fast acting analog of human insulin
31. Pharmacokinetics of a rapid-acting human insulin analog, insulin aspart, in children and adolescents with type 1 diabetes
32. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes
33. LysPro human insulin: Patients treated with LysPro vs human regular insulin: Quality of life assessment
34. LysPro human insulin (LysPro): Patients treated with LysPro vs human regular insulin - Quality of life assessment (QOL)
35. Effect of the insulin analogue LysPro on blood glucose control
36. Effect of the rapid acting insulin analog insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients